Skip to main content

Tug of War Inside the Heart: Mechanism of Secondary Mitral Regurgitation

The imbalance between tethering and closing forces results in secondary mitral regurgitation.

Tug of War Inside the Heart: Understanding Secondary Mitral Regurgitation


Secondary mitral regurgitation (SMR), also called functional mitral regurgitation, is not primarily a disease of the mitral valve leaflets themselves. Instead, it occurs due to distortion of left ventricular geometry, leading to an imbalance between tethering and closing forces of the mitral valve.



---


What is Secondary Mitral Regurgitation?


In secondary MR, the mitral valve leaflets are structurally normal, but the surrounding ventricular apparatus becomes abnormal. The left ventricle dilates or remodels, preventing proper leaflet coaptation during systole, resulting in backward leakage of blood from the left ventricle into the left atrium.


Common causes include:


Ischemic cardiomyopathy


Dilated cardiomyopathy


Chronic heart failure


Left ventricular remodeling after myocardial infarction




---


The Concept of Tethering vs Closing Forces


The mechanism of secondary MR can be understood as a “tug of war” between two opposing forces.


1. Tethering Forces


Tethering forces pull the mitral valve leaflets downward and outward into the ventricle.


They increase when:


Left ventricle dilates


Papillary muscles are displaced


Mitral annulus enlarges


Ventricular remodeling occurs



As tethering increases, the valve leaflets fail to meet properly during systole.


2. Closing Forces


Closing forces are generated by left ventricular systolic contraction and help the mitral valve close tightly.


They decrease when:


LV systolic dysfunction develops


Contractility falls


Stroke volume reduces



Reduced closing force weakens leaflet coaptation.



---


Why the Imbalance Matters


Secondary MR develops when tethering forces exceed closing forces.


This imbalance causes:


Incomplete leaflet coaptation


Central regurgitant jet


Progressive volume overload


Worsening heart failure


Increased mortality risk



The more severe the ventricular remodeling, the greater the tethering and MR severity.



---


Echocardiographic Features


Key echo findings include:


Dilated left ventricle


Reduced LV ejection fraction


Apical leaflet tenting


Increased tenting area and height


Annular dilatation


Central or posteriorly directed MR jet


Papillary muscle displacement



Important measurements:


Effective regurgitant orifice area (EROA)


Regurgitant volume


Vena contracta width


Tenting height and area




---


Clinical Importance


Secondary MR is associated with:


Recurrent heart failure admissions


Reduced exercise tolerance


Pulmonary hypertension


Poor long-term prognosis



Severity of MR may fluctuate depending on preload, afterload, and hemodynamic status.



---


Treatment Strategies


Management focuses primarily on the underlying ventricular disease.


Guideline-Directed Medical Therapy (GDMT)


ACE inhibitors / ARNI


Beta blockers


Mineralocorticoid receptor antagonists


SGLT2 inhibitors


Diuretics



Device Therapy


Cardiac resynchronization therapy (CRT) in selected patients


ICD when indicated



Transcatheter or Surgical Intervention


Selected symptomatic patients may benefit from:


Transcatheter edge-to-edge repair (TEER/MitraClip)


Surgical repair or replacement



Patient selection depends on:


LV dimensions


Pulmonary pressures


RV function


Severity of MR


Response to GDMT




---


Key Takeaway


Secondary mitral regurgitation is fundamentally a ventricular disease rather than a primary valve disorder. The imbalance between increased tethering forces and reduced closing forces prevents proper mitral leaflet coaptation, leading to regurgitation and worsening heart failure.


Understanding this mechanism is essential for accurate echocardiographic assessment and optimal therapeutic decision-making.




Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...